140
Participants
Start Date
August 31, 2007
Primary Completion Date
June 30, 2011
Study Completion Date
June 30, 2012
ABT-869 .25 mg/kg
Subjects will take linifanib (ABT-869) based on body weight. Dosing will be determined at baseline and will be based on randomization to either 0.10 mg or 0.25 mg of ABT-869 per kilogram of body weight.
ABT-869 0.10 mg/kg
Subjects will take linifanib (ABT-869) based on body weight. Dosing will be determined at baseline and will be based on randomization to either 0.10 mg or 0.25 mg of ABT-869 per kilogram of body weight.
Site Reference ID/Investigator# 5640, Taipei
Site Reference ID/Investigator# 7756, Marseille
Site Reference ID/Investigator# 5652, Buffalo
Site Reference ID/Investigator# 7868, Newark
Site Reference ID/Investigator# 6777, Greensboro
Site Reference ID/Investigator# 6184, Charlotte
Site Reference ID/Investigator# 8068, Toulouse
Site Reference ID/Investigator# 7616, Port Saint Lucie
Site Reference ID/Investigator# 5650, Memphis
Site Reference ID/Investigator# 5663, Taichung
Site Reference ID/Investigator# 5269, Indianapolis
Site Reference ID/Investigator# 6739, Evanston
Site Reference ID/Investigator# 8100, Harvey
Site Reference ID/Investigator# 5648, Chicago
Site Reference ID/Investigator# 6042, St Louis
Site Reference ID/Investigator# 5617, Los Angeles
Site Reference ID/Investigator# 7194, Fountain Valley
Site Reference ID/Investigator# 8069, Villejuif
Site Reference ID/Investigator# 7934, Sacramento
Site Reference ID/Investigator# 5660, Singapore
Site Reference ID/Investigator# 5534, Singapore
Site Reference ID/Investigator# 5646, Aurora
Site Reference ID/Investigator# 6627, Waterbury
Site Reference ID/Investigator# 6680, East Orange
Site Reference ID/Investigator# 5603, Voorhees Township
Site Reference ID/Investigator# 6040, Barrie
Site Reference ID/Investigator# 5275, Ottawa
Site Reference ID/Investigator# 6572, Toronto
Collaborators (1)
Genentech, Inc.
INDUSTRY
AbbVie (prior sponsor, Abbott)
INDUSTRY